Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aradigm Corporation    ARDM

ARADIGM CORPORATION (ARDM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
1.43(c) 1.497(c) 1.47(c) 1.49(c) 1.51 Last
5 801 17 648 49 925 13 299 10 446 Volume
-2.05% +4.69% -1.80% +1.36% +1.34% Change
More quotes
Financials (USD)
Sales 2018 0,04 M
EBIT 2018 -12,4 M
Net income 2018 -16,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 559x
Capi. / Sales2019 -
Capitalization 22,4 M
More Financials
Company
Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists.Its technologies include diabetes and pain management, AERx essence... 
More about the company
Latest news on ARADIGM CORPORATION
07/10ARADIGM : Announces the Appointment of Dr. Theresa Matkovits to the Board of Dir..
AQ
07/06ARADIGM CORP : Material Modification to Rights of Security Holders, Change in Di..
AQ
07/06ARADIGM : Announces the Appointment of Dr. Theresa Matkovits to the Board of Dir..
BU
06/14ARADIGM CORP : Creation of a Direct Financial Obligation or an Obligation under ..
AQ
06/06ARADIGM CORP : Change in Directors or Principal Officers, Other Events, Financia..
AQ
05/25ARADIGM : Announces First Quarter 2018 Financial Results
AQ
05/18ARADIGM CORPORATION (NASDAQ : ARDM) Files An 8-K Creation of a Direct Financial ..
AQ
05/17ARADIGM CORP : Creation of a Direct Financial Obligation or an Obligation under ..
AQ
05/15ARADIGM CORPORATION (NASDAQ : ARDM) Files An 8-K Results of Operations and Finan..
AQ
05/15ARADIGM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/16He's a local author and he's got a new book out. David Bell tells and where..
1
07/10As a proud Honorary Graduate of , I wish the new Vice Chancellor, Sir David B.. 
07/06Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Di.. 
07/06Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Di.. 
07/03Critical Review: AxoGen, Inc Common Stock $AXGN versus Aradigm $ARDM  
More tweets
Qtime:91
News from SeekingAlpha
06/21Midday Gainers / Losers (06/21/2018) 
05/15Aradigm reports Q1 results 
05/01HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/01/2018) 
04/17HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (04/17/2018) 
04/06YOUR DAILY PHARMA SCOOP : Conatus Setback, Applied DNA Signs Agreement, Evolus A.. 
Chart ARADIGM CORPORATION
Duration : Period :
Aradigm Corporation Technical Analysis Chart | ARDM | US0385054004 | 4-Traders
Technical analysis trends ARADIGM CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
John M. Siebert Executive Chairman, Chief Executive Officer & CFO
David Cipolla Vice President-Preclinical R&D
Frederick M. Hudson Director
Edwin Gordon Director
Theresa Matkovits Director
Sector and Competitors
1st jan.Capitalization (M$)
ARADIGM CORPORATION-77.76%22
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250